Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting
PR Newswire
May 5, 2025
Immorta Bio was selected to present alongside Pfizer and the University of Pittsburgh at the 2025 American Association of Immunologists Annual Meeting in Honolulu. The company unveiled new data on SenoVax™, its first-in-class senolytic immunotherapy that trains the immune system to target senescent cells—offering a novel approach to treating both cancer and aging.
